<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33360231</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-866X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>51</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Seminars in arthritis and rheumatism</Title>
          <ISOAbbreviation>Semin Arthritis Rheum</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antisynthetase syndrome - much more than just a myopathy.</ArticleTitle>
        <Pagination>
          <StartPage>72</StartPage>
          <EndPage>83</EndPage>
          <MedlinePgn>72-83</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semarthrit.2020.09.020</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0049-0172(20)30308-5</ELocationID>
        <Abstract>
          <AbstractText>The aim of the study was to summarize current knowledge on antisynthetase syndrome (ASS), including its epidemiology, pathogenesis, proposed so far diagnostic criteria, heterogeneity of clinical manifestations, prognostic factors and therapeutic possibilities. PubMed database was screened for "antisynthetase syndrome" OR "antisynthetase antibodies" between February and April 2020. Aminoacyl-tRNA synthetases participate in the immune system activation as antigens, but also serve chemoattractive and cytokine-resembling roles, initiating innate and adaptive pathways. Exposure to various inhaled antigens may induce the autoimmune cascade leading to ASS. NK cells with its impaired INF-y production as well as formation of NETs by neutrophils contribute to pathogenesis. The prevalence of symptoms vary significantly depending on the study with muscular, articular and pulmonary involvement being the most frequently observed. Although classified as subtype of idiopathic inflammatory myopathies, myositis may not necessarily be the prominent manifestation. Since clinical presentation is heterogeneous and symptoms can emerge gradually, ASS could be considered as a heterogeneous spectrum rather than a homogenous disease entity. The currently available classification criteria do not fully correspond with the clinical patterns of the disease. Therapy is based on glucocorticosteroids and other immunosuppressive agents. Randomized controlled trials, dedicated for patients with ASS, are needed to form treatment algorithms.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Opinc</LastName>
            <ForeName>Aleksandra Halina</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Medical University of Lodz, ul. Pieniny 30, 92-115 Łódź, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Makowska</LastName>
            <ForeName>Joanna Samanta</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Medical University of Lodz, ul. Pieniny 30, 92-115 Łódź, Poland. Electronic address: joanna.makowska@umed.lodz.pl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Semin Arthritis Rheum</MedlineTA>
        <NlmUniqueID>1306053</NlmUniqueID>
        <ISSNLinking>0049-0172</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.1.1.-</RegistryNumber>
          <NameOfSubstance UI="D000604">Amino Acyl-tRNA Synthetases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C537778">Antisynthetase syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000604" MajorTopicYN="Y">Amino Acyl-tRNA Synthetases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009135" MajorTopicYN="Y">Muscular Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Antisynthetase antibodies</Keyword>
        <Keyword MajorTopicYN="Y">Antisynthetase syndrome</Keyword>
        <Keyword MajorTopicYN="Y">Arthritis</Keyword>
        <Keyword MajorTopicYN="Y">Idiopathic inflammatory myopathy</Keyword>
        <Keyword MajorTopicYN="Y">Interstitial lung disease</Keyword>
        <Keyword MajorTopicYN="Y">Myositis</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest None.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>11</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33360231</ArticleId>
        <ArticleId IdType="doi">10.1016/j.semarthrit.2020.09.020</ArticleId>
        <ArticleId IdType="pii">S0049-0172(20)30308-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
